Skip to main content

Advertisement

Springer Nature Link
Log in

Oncologic Anthropology: An Interdisciplinary Approach to Understanding the Association Between Genetically Defined African Ancestry and Susceptibility for Triple Negative Breast Cancer

  • Breast Cancer Disparities (LA Newman, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Purpose of Review

This review aims to present contemporary research regarding the association between genetic/germline African ancestry and risk of triple negative breast cancer (TNBC).

Recent Findings

TNBC is more common in African American compared to White American women and contributes to breast cancer outcome disparities. Variation in the frequency of TNBC across different regions of Africa suggests that population migration (the African diaspora) and the genetics of African ancestry contribute to this epidemiology. Our group has coined the nomenclature “oncologic anthropology” to describe the study of these global breast cancer patterns. Cancer-associated founder mutations which have been identified for most ancestral heritage groups represent examples of oncologic anthropology. Herein, we present the expanding body of research related to the Duffy antigen receptor for chemokines (DARC)/atypical chemokine receptor 1 (ACKR1) and its association with cancer-related cytokines as a factor in the etiology of differences in breast cancer burden. DARC/ACKR1 expression on erythrocytes is also widely known as the “Duffy blood group,” and the genotype resulting in its absence (Duffy-null) was under strong evolutionary selection pressure in western, sub-Saharan Africa several thousand years ago because of the protection afforded by this phenotype against malaria pathogens. The Duffy-null allele is therefore nearly fixed among populations in this region of Africa, and it has varying prevalence among populations with admixed western sub-Saharan African ancestry (such as African Americans and East Africans).

Summary

Recently characterized associations between an African ancestry-specific DARC/ACKR1 variant, breast tumor DARC/ACKR1 expression, and DARC/ACKR1 influence on cancer-associated chemokines indicate that this gene is important in understanding disease progression as well as breast cancer disparities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Ca Epi Bio Prev. 2015;24(10):1495–506.

  2. Rose C, Stovall E, Ganz PA, Desch C, Hewitt M. Cancer quality alliance: blueprint for a better cancer care system. CA Cancer J Clin. 2008;58(5):266–92.

    Article  PubMed  Google Scholar 

  3. • Newman LA, Kaljee LM. Health disparities and triple-negative breast cancer in African American women: a review. JAMA surgery. 2017;152(5):485-08. Review of breast cancer phenotypes in women of African ancestry on a worldwide basis.

  4. Newman LA, Reis-Filho JS. Morrow M, Carey LA, King TA. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol. 2015;22(3):874–82.

    Article  PubMed  Google Scholar 

  5. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016.

  6. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254–8.

    Article  PubMed  Google Scholar 

  7. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Jiagge E, Jibril AS, Chitale D, Bensenhaver JM, Awuah B, Hoenerhoff M, et al. Comparative analysis of breast cancer phenotypes in African American, White American, and West Versus East African patients: correlation between African ancestry and triple-negative breast cancer. Ann Surg Oncol. 2016;23(12):3843–9.

    Article  PubMed  Google Scholar 

  9. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 incidence and mortality web-based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016. Available at: www.cdc.gov/uscs. Accessed September 6, 2016, 2016.

  10. Force USPST, Owens DK, Davidson KW, et al. Risk assessment, genetic counseling, and genetic testing for brca-related cancer: US preventive services task force recommendation statement. Jama. 2019;322(7):652–65.

    Article  Google Scholar 

  11. Li S, Schlebusch C, Jakobsson M. Genetic variation reveals large-scale population expansion and migration during the expansion of Bantu-speaking peoples. Proc Biol Sci. 2014;281(1793).

  12. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 2006;295(21):2492–502.

    Article  CAS  PubMed  Google Scholar 

  13. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876–84.

    Article  PubMed  Google Scholar 

  14. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer. 2008;113(3):608–15.

    Article  PubMed  Google Scholar 

  15. Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer. 2008;113(9):2565–74.

    Article  PubMed  Google Scholar 

  16. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta. GA Breast Cancer Res Treat. 2009;113(2):357–70.

    Article  PubMed  Google Scholar 

  17. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071–82.

  18. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010;16(24):6100–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Loo LW, Wang Y, Flynn EM, et al. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat. 2011;127(1):297–308.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer. 2011;117(12):2747–53.

    Article  PubMed  Google Scholar 

  21. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463–72.

    Article  PubMed  Google Scholar 

  22. Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, et al. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat. 2014;144(3):689–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer. 2014;14:62.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 2015;33(20):2254–61.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, et al. Comparison of the genomic landscape between primary breast cancer in African American versus White women and the association of racial differences with tumor recurrence. J Clin Oncol. 2015;33(31):3621–7.

  26. Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX. Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. Breast Cancer Res Treat. 2017;161(3):491–9.

    Article  CAS  PubMed  Google Scholar 

  27. Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas. JAMA oncology. 2017;3(12):1654–62.

    Article  PubMed  PubMed Central  Google Scholar 

  28. • Troester MA, Sun X, Allott EH, et al. Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018;110(2) This study provides novel data regarding intrinsic breast cancer subtypes in African American compared to White American women based upon the population-based Carolina Breast Cancer Study.

  29. Foy KC, Fisher JL, Lustberg MB, Gray DM, DeGraffinreid CR, Paskett ED. Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women. NPJ breast cancer. 2018;4:7.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am. 2014;23(3):567–77.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Davis MB, Newman LA. Breast cancer disparities: how can we leverage genomics to improve outcomes? Surg Oncol Clin N Am. 2018;27(1):217–34.

    Article  PubMed  Google Scholar 

  32. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–8.

    Article  PubMed  Google Scholar 

  33. • DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42 This report provides data on shifting population-based breast cancer incidence rates in African American and White American women.

    Article  PubMed  Google Scholar 

  34. Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas. JAMA oncology. 2017;3:1654–62.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast cancer research : BCR. 2007;9(3):R28.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Gakinya SM, Sayed S, Chauhan R, Sayed P. Breast cancer molecular subtypes and their clinicopathological characteristics amongst patients at the Aga Khan University Hospital (Nairobi). Ann Afr Surg. 2010;5:19–24.

    Article  Google Scholar 

  37. Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol. 2008;15(7):1983–8.

    Article  CAS  PubMed  Google Scholar 

  38. Nyagol J, Nyong'o A, Byakika B, Muchiri L, Cocco M, de Santi MM, et al. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Anal Quant Cytol Histol. 2006;28(2):97–103.

    PubMed  Google Scholar 

  39. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Frequency of the basal-like phenotype in African breast cancer. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. Acta Path Micro Immunol Scand. 2007;115(12):1391–9.

  40. Roy I, Othieno E. Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med. 2011;135(2):194–9.

    Article  PubMed  Google Scholar 

  41. Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Govender D, et al. Is breast cancer from sub-Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Breast. 2014;23(5):591–6.

    Article  PubMed  Google Scholar 

  42. Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A. Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population. Pan Afr Med J. 2014;17:249.

    PubMed  PubMed Central  Google Scholar 

  43. Sawe RT, Kerper M, Badve S, Li J, Sandoval-Cooper M, Xie J, et al. Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer. 2016;16:204.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Sengal AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, Kantelhardt EJ, Mohamedani AA. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series. BMC Cancer. 2017;17(1):804.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Shaikh AJ, Mullooly M, Sayed S, et al. Mammographic breast density and breast cancer molecular subtypes: the Kenyan-African aspect. Biomed Res Int. 2018;2018:6026315.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Eber-Schulz P, Tariku W. Reibold C, et al. Breast Cancer Res Treat: Survival of breast cancer patients in rural Ethiopia; 2018.

    Google Scholar 

  47. Hadgu E, Seifu D, Tigneh W, Bokretsion Y, Bekele A, Abebe M, et al. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health. 2018;18(1):40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Njoroge FW, et al. Ethnicity and breast cancer characteristics in Kenya. Breast Cancer Res Treat. 2018;167(2):425–37.

    Article  PubMed  Google Scholar 

  49. • Newman LA, Jenkins B, Chen Y, et al. Hereditary susceptibility for triple negative breast cancer associated with western sub-Saharan African ancestry: results from an international surgical breast cancer collaborative. Ann Surg. 2019;270(3):484–92 This study provides novel genetics data regarding the association between germline western sub-Saharan African ancestry and risk of triple negative breast cancer related to the Duffy Antigen.

    Article  PubMed  Google Scholar 

  50. Fourati A, Boussen H, El May MV, et al. Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia Pac J Clin Oncol. 2014;10(2):e69–74.

    Article  PubMed  Google Scholar 

  51. Rais G, Raissouni S, Aitelhaj M, Rais F, Naciri S, Khoyaali S, et al. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health. 2012;12:35.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Bennis S, Abbass F, Akasbi Y, Znati K, Joutei KA, el Mesbahi O, et al. Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC research notes. 2012;5:436.

    Article  PubMed  PubMed Central  Google Scholar 

  53. El-Hawary AK, Abbas AS, Elsayed AA, Zalata KR. Molecular subtypes of breast carcinoma in Egyptian women: clinicopathological features. Pathol Res Pract. 2012;208(7):382–6.

    Article  CAS  PubMed  Google Scholar 

  54. Salhia B, Tapia C, Ishak EA, Gaber S, Berghuis B, Hussain KH, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health. 2011;11:44.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, et al. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. Breast disease. 2015;35:95–102.

    Article  PubMed  Google Scholar 

  56. Aiad HA, Wahed MM, Asaad NY, El-Tahmody M, Elhosary E. Immunohistochemical expression of GPR30 in breast carcinoma of Egyptian patients: an association with immunohistochemical subtypes. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. Acta Path Micro Immunol Scand. 2014;122(10):976–84.

  57. Elidrissi Errahhali M, Elidrissi Errahhali M, Ouarzane M, El Harroudi T, Afqir S, Bellaoui M. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. BMC Womens Health. 2017;17(1):3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Derkaoui T, Bakkach J, Mansouri M, Loudiyi A, Fihri M, Alaoui FZ, et al. Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features. BMC Womens Health. 2016;16(1):68.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Bogan D, Meile L, El Bastawisy A, et al. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion. BMC Cancer. 2017;17(1):329.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, Fihri M, Hassani S, et al. Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco. BMC Womens Health. 2017;17(1):106.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Souad H, Zahia F, Abdelhak L, Karima S, Dalila S, Noureddine A. Descriptive study of triple negative breast cancer in Eastern Algeria. Pan Afr Med J. 2018;29:45.

    PubMed  PubMed Central  Google Scholar 

  62. Luyeye Mvila G, Batalansi D, Praet M, Marchal G, Laenen A, Christiaens MR, et al. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium. Breast. 2015;24(5):642–8.

    Article  PubMed  Google Scholar 

  63. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat. 2008;110(1):183–8.

    Article  CAS  PubMed  Google Scholar 

  64. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009;27(27):4515–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Ly M, Antoine M, Dembele AK, et al. High incidence of triple-negative tumors in sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology. 2012;83(5):257–63.

    Article  PubMed  Google Scholar 

  66. Ohene-Yeboah M, Adjei E. Breast cancer in Kumasi, Ghana. Ghana Med J. 2012;46(1):8–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Adjei EK, Owusu-Afriyie O, Awuah B, Stalsberg H. Hormone receptors and Her2 expression in breast cancer in sub-Saharan Africa. A comparative study of biopsies from Ghana and Norway. Breast J. 2014;20(3):308–11.

    Article  PubMed  Google Scholar 

  68. Der EM, Gyasi RK, Tettey Y, et al. Triple-negative breast cancer in Ghanaian women: the Korle Bu Teaching Hospital Experience. Breast J. 2015;21(6):627–33.

    Article  CAS  PubMed  Google Scholar 

  69. Nwafor CC, Keshinro SO. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: private practice experience. Niger J Clin Pract. 2015;18(4):553–8.

    Article  CAS  PubMed  Google Scholar 

  70. Titloye NA, Foster A, Omoniyi-Esan GO, Komolafe AO, Daramola AO, Adeoye OA, et al. Histological features and tissue microarray taxonomy of Nigerian breast cancer reveal predominance of the high-grade triple-negative phenotype. Pathobiology. 2016;83(1):24–32.

    Article  CAS  PubMed  Google Scholar 

  71. Miguel F, Lopes LV, Ferreira E, et al. Breast cancer in Angola, molecular subtypes: a first glance. Ecancermedicalscience. 2017;11:763.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018;9(1):4181.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. McCormack VA, Joffe M, van den Berg E, et al. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Br Ca Res. 2013;15(5):R84.

  74. Dickens C, Duarte R, Zietsman A, Cubasch H, Kellett P, Schüz J, et al. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Ca Epi Bio Prev. 2014;23(11):2311–21.

  75. Dickens C, Pfeiffer RM, Anderson WF, Duarte R, Kellett P, Schüz J, et al. Investigation of breast cancer sub-populations in black and white women in South Africa. Breast Cancer Res Treat. 2016;160(3):531–7.

    Article  PubMed  Google Scholar 

  76. Cubasch H, Joffe M, Ruff P, Dietz D, Rosenbaum E, Murugan N, et al. Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa. PloS one. 2017;12(8):e0182125.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Ruff P, Cubasch H, Joffe M, Rosenbaum E, Murugan N, Tsai MC, et al. Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa. Cancer Manag Res. 2018;10:279–86.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Joffe M, Ayeni O, Norris SA, McCormack VA, Ruff P, Das I, et al. Barriers to early presentation of breast cancer among women in Soweto, South Africa. PLoS One. 2018;13(2):e0192071.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet. 2005;77(2):171–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Hedrick PW. Population genetics of malaria resistance in humans. Heredity (Edinb). 2011;107(4):283–304.

    Article  CAS  Google Scholar 

  81. Chaudhuri A, Zbrzezna V, Johnson C, Nichols M, Rubinstein P, Marsh WL, et al. Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity. Possible receptor for Plasmodium vivax and Plasmodium knowlesi malaria parasite. J Biol Chem. 1989;264(23):13770–4.

    Article  CAS  PubMed  Google Scholar 

  82. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995;10(2):224–8.

    Article  CAS  PubMed  Google Scholar 

  83. Tournamille C, Le Van Kim C, Gane P, Cartron JP, Colin Y. Molecular basis and PCR-DNA typing of the Fya/fyb blood group polymorphism. Hum Genet. 1995;95(4):407–10.

    Article  CAS  PubMed  Google Scholar 

  84. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, et al. The global distribution of the Duffy blood group. Nat Commun. 2011;2:266.

    Article  PubMed  CAS  Google Scholar 

  85. Yazdanbakhsh K, Rios M, Storry JR, Kosower N, Parasol N, Chaudhuri A, et al. Molecular mechanisms that lead to reduced expression of duffy antigens. Transfusion. 2000;40(3):310–20.

    Article  CAS  PubMed  Google Scholar 

  86. Schmid P, Ravenell KR, Sheldon SL, Flegel WA. DARC alleles and Duffy phenotypes in African Americans. Transfusion. 2012;52(6):1260–7.

    Article  CAS  PubMed  Google Scholar 

  87. • Davis MB, Walens A, Hire R, et al. Distinct transcript isoforms of the atypical chemokine receptor 1 (ACKR1)/Duffy antigen receptor for chemokines (darc) gene are expressed in lymphoblasts and altered isoform levels are associated with genetic ancestry and the Duffy-null allele. PLoS One. 2015;10(10):e0140098 This study provides novel data regarding the function and expression of the Duffy gene and its protein.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Cutbush M, Mollison PL. The Duffy blood group system. Heredity (Edinb). 1950;4(3):383–9.

    Article  CAS  Google Scholar 

  89. Mason SJ, Miller LH, Shiroishi T, Dvorak JA, McGinniss MH. The Duffy blood group determinants: their role in the susceptibility of human and animal erythrocytes to Plasmodium knowlesi malaria. Br J Haematol. 1977;36(3):327–35.

    Article  CAS  PubMed  Google Scholar 

  90. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295(6):302–4.

    Article  CAS  PubMed  Google Scholar 

  91. Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science. 1975;189(4202):561–3.

    Article  CAS  PubMed  Google Scholar 

  92. Nibbs RJ, Graham GJ. Immune regulation by atypical chemokine receptors. Nat Rev Immunol. 2013;13(11):815–29.

    Article  PubMed  CAS  Google Scholar 

  93. Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol. 2009;10(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  94. Neote K, Mak JY, Kolakowski LF Jr, Schall TJ. Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood. 1994;84(1):44–52.

    Article  CAS  PubMed  Google Scholar 

  95. Thobakgale CF, Ndung'u T. Neutrophil counts in persons of African origin. Curr Opin Hematol. 2014;21(1):50–7.

    Article  PubMed  Google Scholar 

  96. Reich D, Nalls MA, Kao WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet. 2009;5(1):e1000360.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Yao S, Hong CC, Ruiz-Narvaez EA, et al. Genetic ancestry and population differences in levels of inflammatory cytokines in women: role for evolutionary selection and environmental factors. PLoS Genet. 2018;14(6):e1007368.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146(7):486–92.

    Article  PubMed  Google Scholar 

  99. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med. 1999;133(1):15–22.

    Article  CAS  PubMed  Google Scholar 

  100. Akalin E, Neylan JF. The influence of Duffy blood group on renal allograft outcome in African Americans. Transplantation. 2003;75(9):1496–500.

    Article  CAS  PubMed  Google Scholar 

  101. Hansell CA, Hurson CE, Nibbs RJ. DARC and D6: silent partners in chemokine regulation? Immunol Cell Biol. 2011;89(2):197–206.

    Article  CAS  PubMed  Google Scholar 

  102. Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J, et al. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene. 2006;25(54):7201–11.

    Article  CAS  PubMed  Google Scholar 

  103. Wang J, Ou ZL, Hou YF, Luo JM, Chen Y, Zhou J, et al. Duffy antigen receptor for chemokines attenuates breast cancer growth and metastasis: an experiment with nude mice. Zhonghua Yi Xue Za Zhi. 2005;85(29):2033–7.

    CAS  PubMed  Google Scholar 

  104. Liu XF, Li LF, Ou ZL, Shen R, Shao ZM. Correlation between Duffy blood group phenotype and breast cancer incidence. BMC Cancer. 2012;12:374.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Jenkins BD, Martini RN, Hire R, et al. Atypical chemokine receptor 1 (DARC/ACKR1) in breast tumors is associated with survival, circulating chemokines, tumor infiltrating immune cells and African ancestry. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Ca Epi Bio Prev. 2019.

  106. Newman LA, Oppong JK, Jibril AS, et al. Hereditary susceptibility for triple negative breast cancer associated with western sub-Saharan African Ancestry: results from an international surgical breast cancer collaborative. Paper presented at: American Surgical Association; April 2019, 2019; Dallas, TX.

  107. Lynce F, Saleh M, Shajahan-Haq A, Gallagher C, Dilawari A, Hahn O, et al. PALINA: a phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemp Clin Trials Commun. 2018;10:190–2.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J. 2006;20(1):59–64.

    Article  CAS  PubMed  Google Scholar 

  109. Lentsch AB. The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? FASEB J. 2002;16(9):1093–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and International Center for the Study of Breast Cancer Subtypes, Weill Cornell Medicine, 525 East 68th Street, New York, NY, USA

    Melissa B. Davis & Lisa A. Newman

Authors
  1. Melissa B. Davis
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Lisa A. Newman
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Lisa A. Newman.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Breast Cancer Disparities

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis, M.B., Newman, L.A. Oncologic Anthropology: An Interdisciplinary Approach to Understanding the Association Between Genetically Defined African Ancestry and Susceptibility for Triple Negative Breast Cancer. Curr Breast Cancer Rep 13, 247–258 (2021). https://doi.org/10.1007/s12609-021-00426-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-021-00426-y

Keywords